News | November 12, 2021
Covaxin well tolerated with no safety concerns: Lancet
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Covaxin is the only Covid-19 vaccine to have demonstrated efficacy data from phase III clinical trials against the Delta variant at 65.2%
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
ABB Drives play a key role in the cleanroom infrastructure of Bharat Biotech, India’s first indigenous Covid-19 vaccine manufacturer. The drives are easy to commission, use and ensure higher energy efficiency
Sputnik Light is the first component (recombinant human adenovirus serotype number 26 (rAd26)) of Sputnik
The trial will enroll approximately 468 patients
The collaboration brings together expertise in healthcare and early education to support children during their formative years and empower parents with evidence-based guidance
The facility comes at a time when demand for women's healthcare solutions is rising globally, driven by increasing awareness and diagnosis of hormonal disorders, growing demand for fertility treatments
The proposed changes seek to shorten the statutory timelines for granting manufacturing licences across various risk categories
The study also met its key secondary endpoint for bone health
Subscribe To Our Newsletter & Stay Updated
